RxDoctor Payments Data

John Katopodis, MD

Cardiovascular Disease · Tallahassee, FLNPI 1477559623

Payments from drug & device makers

$111,167in general payments, 2019–2025

Across 288 payments — averaging $386.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$76K
  • EKOS Corporation$15K
  • Merck$7K
  • Boston Scientific$4K
  • Cardiovascular Systems Inc.$2K
  • Abiomed$1K
  • plus $7K from 30 others

What the payments were for

  • Speaking & faculty fees$4004%
  • Travel & lodging$1,35512%
  • Food & beverage$9,43484%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$111,167 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$182,849
Medicare patients
661
Services billed
1,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$162,931
XareltoRivaroxaban124$104,636
EntrestoSacubitril/Valsartan74$86,479
FarxigaDapagliflozin Propanediol77$73,520
JardianceEmpagliflozin47$51,256
Metoprolol Succinate593$14,998
Repatha SureclickEvolocumab14$9,631
BrilintaTicagrelor11$7,051
Atorvastatin Calcium376$6,415
Ranolazine ErRanolazine81$5,803
Rosuvastatin Calcium259$4,502
Nadolol14$4,501
Ezetimibe105$2,103
Losartan Potassium151$2,091
Isosorbide Mononitrate ErIsosorbide Mononitrate110$1,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$162,931138 claims
Johnson & JohnsonXarelto$39$104,636124 claims
AstraZenecaFarxiga, Brilinta$13$80,57188 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →